EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prediabetes and diabetes mellitus type II after ischemic stroke

Kurt Moelgg iD, Anel Karisik iD, Lukas Scherer, Lucie Buergi, Benjamin Dejakum, Silvia Komarek, Julian Granna iD, Christian Boehme iD, Raimund Pechlaner, Thomas Toell iD, Michael Knoflach, Stefan Kiechl und 4 weitere

European Stroke Journal · 2025

DOI: 10.1177/23969873241304301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Stroke Journal, 2025. Verfasst von Kurt Moelgg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Prediabetic State, Ischemic Stroke. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VASCage, Centre on Clinical Stroke Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The progression of diabetes status in post-stroke patients remains under-investigated, particularly regarding new treatments for type II diabetes mellitus (DM II), like glucagon-like peptide 1 receptor agonists (GLP-1-RA) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, which have not been studied in the post-stroke setting. Patients and methods Eight hundred eighty-four consecutive ischemic stroke patients recruited to our prospective STROKE-CARD Registry were assessed concerning their glycemic status at baseline (normoglycemia, prediabetes, DM II) and change over time within 1 year follow-up. Multivariate logistic regression was performed to identify factors associated with transitioning from normoglycemia to prediabetes or DM II. Additionally, we reviewed ongoing clinical trials for GLP-1-RA and SGLT-2 inhibitors in the context of acute ischemic stroke.

Results

At baseline, 44.6% (n = 394) of individuals had normoglycemia, 33.9% (n = 300) were prediabetic, and 21.5% had DM II (n = 190). After 1 year, normoglycemia decreased by 12.1 percentage points (n = 107), whereas prediabetes and DM II increased by 10.2 percentage (n = 90) points and 1.9 percentage points (n = 17), respectively. Statin therapy was the only significant risk factor for progression. 23.4% (n = 207) of our cohort would have met eligibility criteria for a recent trial on semaglutide in obese non-diabetics with prior cardiovascular disease. However, only one ongoing trial aims at evaluating short-term cardiovascular risk reduction in stroke patients.

Discussion

GPrediabetes and DM II are frequent in ischemic stroke patients. Even within an intensified post-stroke disease management setting, a considerable amount of stroke survivors convert to prediabetes or DM II within the first year. Our results demonstrate a notable proportion of patients qualifying inclusion in studies examining the efficacy of GLP-1-RA agonists and SGLT-2 inhibitors in secondary prevention.

Conclusion

Given the high prevalence and progression of prediabetes and DM II in stroke survivors, there is a need for clinical trials evaluating the use of GLP-1-RA and SGLT-2 inhibitors in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Prediabetic StateIschemic StrokeHumansMaleFemaleAgedMiddle AgedProspective StudiesRegistriesSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsBlood GlucoseAged, 80 and overDisease Progression

Stichwörter der Autor:innen

Prediabetesantidiabetic therapycardiovascular risk factorsischemic strokesecondary preventiontype II diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • VASCage, Centre on Clinical Stroke Research, Innsbruck, Austria.
  • Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.
  • Central Institute of Clinical Chemistry and Laboratory Medicine, Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Kurt Moelgg, Anel Karisik, Julian Granna, Christian Boehme, Thomas Toell, Lukas Mayer-Suess

Förderung

  • VASCage, Centre on Clinical Stroke Research

Zitieren

APA

Moelgg, K., Karisik, A., Scherer, L., Buergi, L., Dejakum, B., Komarek, S., Granna, J., Boehme, C., Pechlaner, R., Toell, T., Knoflach, M., Kiechl, S., Kaser, S., Egger, A., Griesmacher, A., & Mayer-Suess, L. (2025). Prediabetes and diabetes mellitus type II after ischemic stroke. European Stroke Journal. https://doi.org/10.1177/23969873241304301

Vancouver

Moelgg K, Karisik A, Scherer L, Buergi L, Dejakum B, Komarek S, et al. Prediabetes and diabetes mellitus type II after ischemic stroke. European Stroke Journal. 2025. doi:10.1177/23969873241304301

BibTeX
@article{Moelgg2025,
  author = {Moelgg, Kurt and Karisik, Anel and Scherer, Lukas and Buergi, Lucie and Dejakum, Benjamin and Komarek, Silvia and Granna, Julian and Boehme, Christian and Pechlaner, Raimund and Toell, Thomas and Knoflach, Michael and Kiechl, Stefan and Kaser, Susanne and Egger, Alexander and Griesmacher, Andrea and Mayer-Suess, Lukas},
  title = {Prediabetes and diabetes mellitus type II after ischemic stroke},
  journal = {European Stroke Journal},
  year = {2025},
  doi = {10.1177/23969873241304301}
}
Kostenlos starten →